Consumption of whole grains and legumes modulates the genetic effect of the APOA5 -1131C variant on changes in triglyceride and apolipoprotein A-V concentrations in patients with impaired fasting glucose or newly diagnosed type 2 diabetes

Trials. 2014 Apr 1:15:100. doi: 10.1186/1745-6215-15-100.

Abstract

Background: The apolipoprotein A5 gene (APOA5) -1131 T > C polymorphism is associated with mild hypertriglyceridemia in type 2 diabetic subjects, and interacts with dietary fat in the determination of triglyceride concentrations. We examined whether a substitution of whole grains and legumes for refined rice in a high carbohydrate diet (about 65% of energy derived from carbohydrate) may modify the effect of this variant on changes in apolipoprotein A-V (apoA-V) and triglyceride concentrations.

Methods: We genotyped the APOA5 -1131 T > C in individuals with impaired fasting glucose (IFG) or newly diagnosed type 2 diabetes, who were randomly assigned to either a group ingesting whole grain and legume meals daily or a control group for 12 weeks.

Results: After dietary intervention, we observed significant interactions between the APOA5 -1131 T > C polymorphism and carbohydrate sources (whole grains and legumes versus refined rice) in the determination of mean percent changes in triglyceride and apoA-V (P interactions <0.001 and =0.038, respectively). In the refined rice group (n = 93), the carriers of the risk C allele (n = 50) showed a greater increase in the mean percent changes of triglyceride and apoA-V than noncarriers after adjusting for HOMA-IR (P = 0.004 and 0.021, respectively). The whole grain and legume group (n = 92), however, showed a decrease in fasting glucose, HOMA-IR, and triglyceride, and an increase in apoA-V, irrespective of genotype.

Conclusions: The data showed that the magnitude of the genetic effect of the APOA5 -1131C variant on triglyceride and apoA-V levels was modulated when substituting consumption of whole grains and legumes for refined rice as a carbohydrate source in IFG or diabetic subjects.

Trial registration: ClinicalTrials.gov: NCT01784952.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apolipoprotein A-V
  • Apolipoproteins A / blood*
  • Apolipoproteins A / genetics*
  • Biomarkers / blood
  • Blood Glucose / metabolism*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / diet therapy*
  • Diabetes Mellitus, Type 2 / genetics
  • Dietary Carbohydrates* / adverse effects
  • Edible Grain*
  • Fabaceae*
  • Fasting / blood*
  • Female
  • Genotype
  • Humans
  • Insulin / blood
  • Male
  • Middle Aged
  • Oryza
  • Phenotype
  • Polymorphism, Genetic*
  • Republic of Korea
  • Time Factors
  • Treatment Outcome
  • Triglycerides / blood*

Substances

  • APOA5 protein, human
  • Apolipoprotein A-V
  • Apolipoproteins A
  • Biomarkers
  • Blood Glucose
  • Dietary Carbohydrates
  • Insulin
  • Triglycerides

Associated data

  • ClinicalTrials.gov/NCT01784952